Elinzanetant-d3

Elinzanetant-d3 (NT-814-d3) is deuterium labeled Elinzanetant. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women[1][2][3].

Product Specifications

Product Name Alternative

NT-814-d3; BAY3427080-d3

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Neurokinin Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Smiles

CC(C)(C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C(N(C2=CN=C(N3[C@@H](CN4[C@@](COCC4)([H])C3)CO)C=C2C5=C(C=C(C=C5)F)C)C([2H])([2H])[2H])=O

Molecular Formula

C33H32D3F7N4O3

Molecular Weight

671.66

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Alvaro, Giuseppe; Andreotti, Daniele; Belvedere, Sandro; Di Fabio, Romano; Falchi, Alessandro; Giovannini, Riccardo.Pyridine derivatives as NK receptor inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of psychotic disorders.CN101305011B|[3]Steve Pawsey, et al. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106 (8) :e3221-e3234.|[4]Simon JA, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1) . Menopause. 2023 Mar 1;30 (3) :239-246.